Screener
Arcus Biosciences RCUS Total Assets
Total Assets at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Long-term marketable securities | 73 | 29 |
| Property and equipment, net | 36 | 40 |
| Other noncurrent assets | 59 | 63 |
| Total assets | $924 | $1,139 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable ($12 and $24 to a related party) | $34 | $42 |
| Deferred revenue ($11 and $35 to a related party) | 19 | 35 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's total assets?
- Arcus Biosciences (RCUS) reported total assets of $924M in Q2 2026.
- How has Arcus Biosciences's total assets changed year-over-year?
- Arcus Biosciences's total assets decreased by 14.0% year-over-year, from $1.08B to $924M.
- What is the long-term trend for Arcus Biosciences's total assets?
- Over 5 years (2020 to 2025), Arcus Biosciences's total assets has grown at a 8.1% compound annual growth rate (CAGR), from $772.29M to $1.14B.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Arcus Biosciences's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude